|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2006-8-2
|
|
pubmed:abstractText |
Metformin is considered the gold standard for type 2 diabetes treatment as monotherapy and in combination with sulphonylureas and insulin. The combination of metformin with thiazolidinediones is less well studied. The aim of the present study was to assess the differential effect, and tolerability, of metformin combined with pioglitazone or rosiglitazone on glucose, coagulation and fibrinolysis parameters in patients with type 2 diabetes mellitus and metabolic syndrome.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
0269-4727
|
|
pubmed:author |
pubmed-author:CiccarelliLL,
pubmed-author:CiceroA F GAF,
pubmed-author:D'AngeloAA,
pubmed-author:DerosaGG,
pubmed-author:FerrariII,
pubmed-author:GravinaAA,
pubmed-author:MontagnaLL,
pubmed-author:PanigaSS,
pubmed-author:PiccinniM NMN,
pubmed-author:PricoloFF,
pubmed-author:RagonesiP DPD,
pubmed-author:SalvadeoS A TSA
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
31
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
375-83
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:16882108-Blood Glucose,
pubmed-meshheading:16882108-Diabetes Mellitus, Type 2,
pubmed-meshheading:16882108-Double-Blind Method,
pubmed-meshheading:16882108-Drug Therapy, Combination,
pubmed-meshheading:16882108-Female,
pubmed-meshheading:16882108-Hemoglobin A, Glycosylated,
pubmed-meshheading:16882108-Homocysteine,
pubmed-meshheading:16882108-Humans,
pubmed-meshheading:16882108-Hypoglycemic Agents,
pubmed-meshheading:16882108-Insulin,
pubmed-meshheading:16882108-Male,
pubmed-meshheading:16882108-Metabolic Syndrome X,
pubmed-meshheading:16882108-Metformin,
pubmed-meshheading:16882108-Middle Aged,
pubmed-meshheading:16882108-Thiazolidinediones
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome.
|
|
pubmed:affiliation |
Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy. giuseppe.derosa@unipv.it
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Multicenter Study
|
